An immune-mediated pathogenesis should be considered for dogs with idiopathic neutropenia in which the cause is not known. Severe neutropenia and young age were significantly associated with idiopathic neutropenia in dogs. Prognosis appeared to be excellent with prednisone treatment.
IntroductionA common side effect of treatment with PGI2α and Ribavirin is bone marrow suppression and subsequent neutropaenia. This often results in dose adjustment for fear of rendering patients (pts) more susceptible to serious infection. Our experience is that pts tolerate the neutropaenia without adverse effects and we usually only consider dose reductions if other compelling reasons co-existent. This study was designed to identify the rates of neutropaenia in our treatment group and to determine if they were at greater risk of serious infections.MethodsAll pts who started and completed their treatment for Chronic Hepatitis C infection with combination therapy with PGI2α and ribavirin between April 2006 – September 2009 were included in the study. Three pts failed to attend for follow-up and were excluded from the study. As per BSG guidance, pts had their full blood counts monitored weekly for the first month then monthly thereafter while on treatment. The incidence of serious infection was monitored by reviewing clinical notes and hospital admissions.ResultsTotal number of pts included in the study was 120 (Female=29, Male=91). The genotypes of our patient group were as follows: genotype 1a, 43 pts; genotype 1B, 10 pts; genotype 2a, 2 pts; genotype 2b, 9pts; genotype 3a, 55 pts. Pts with genotype 1 had 48 weeks of treatment and pts with genotype 2 or 3 had 24-week of treatment. Doses were weight adjusted as recommended by national guidelines.Neutropaenia was classified as a neutrophil count <1.5×109/l and was observed in 52 pts (43%) (Female=17, Male=35). The degree of neutropaenia was further subdivided into; Mild 1.0×109/l–1.5×109/l (35 pts); Moderate 0.5×109/l–1.0×109/l (14 pts) and Severe <0.5×109/l (3 pts).Dose adjustments were only advised in 3 pts (2 with co-existent neutropaenia and thrombocytopaenia and 1 with recurrent mouth ulcers). Serious infection requiring hospital admission or discontinuation of treatment was not identified in any pts. Of the pts who developed neutropaenia, 46 (88%) had negative PCR at the end of treatment and 40 pts (77%) had sustained virological response (SVR) at 1 year follow-up.ConclusionAlthough the incidence of neutropaenia in pts treated with PGI2α plus Ribavirin is relatively common (43% in our series), the risk of resultant serious infection appears remote. Neutropaenia appears to be a more frequent occurrence in treated female pts (59% females cf. 38% males, p<0.05). Dose reduction is such pts developing neutropaenia as suggested by current guidance appears to be unnecessary and may diminish the likelihood of viral eradication and SVR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.